Clinical Trial Update: Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial evaluating abemaciclib in combination with bevacizumab for recurrent glioblastoma with CDKN2A/B loss or CDK4/6 amplification has been ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Glioblastoma

Drugs mentioned

• Avastin (bevacizumab)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: GBM, Glioblastoma | EARLY_Phase 1 | Status: TERMINATED